**Issue 101: 8th August 2022**

**Contents:**
- ICARS Newsletter 08.08.22
- JCVI statements: Updates to Childhood schedule and HPV final advice
- Smallpox vaccine Patient Group Direction (PGD)
- Further Information

**ICARS Newsletter 08.08.22**

Please find this week’s ICARS newsletter attached to this email.

**JCVI statements: Updates to Childhood schedule and HPV final advice**

**Childhood schedule statement**

The Joint Committee on Vaccination and Immunisation (JCVI) has been notified of the discontinuation of Menitorix© (Hib/MenC). This necessitates a change to the routine infant schedule as this vaccine is currently given at 12 months.

After careful consideration of the options, the JCVI advises that:

- an additional dose of Hib-containing multivalent vaccine should be offered at 12 or 18 months of ages – note that giving this at 18 months would require the creation of a new immunisation visit
- the second dose of measles, mumps and rubella (MMR) vaccine should be brought forward from 3 years 4 months to 18 months of age to improve coverage
- including a dose of MenC-containing vaccine (such as MenACWY) in the infant schedule is not recommended – efforts to sustain and improve coverage of MenACWY in adolescents are important to maintain herd immunity


**HPV statement**

Final advice on moving to a one dose HPV vaccine schedule for the routine adolescent programme and MSM programme before age 25, 2 dose schedule from
age of 25 in MSM programme and 3 dose schedule for individuals who are immunosuppressed and those known to be HIV-positive.

**Smallpox vaccine Patient Group Direction (PGD)**

Please find attached the updated Smallpox PGD and related documents.

**Further Information**

- Back issues of these bulletins and attachments are available on the NHSEI website [here](#).
- If you have any questions or wish to provide feedback, please contact the Integrated Public Health Team at [england.swscreeningandimms@nhs.net](mailto:england.swscreeningandimms@nhs.net)